Rapport offers a high-risk, high-upside precision neuroscience story built on RAP-219’s differentiated seizure-control profile, strong cash runway, and approaching Phase 3 catalysts.
Overview
Rapport Therapeutics is a clinical-stage precision neuroscience company developing small-molecule CNS therapies, led by RAP-219 for drug-resistant focal epilepsy. Its RAP platform targets disease-relevant brain regions while avoiding areas tied to systemic side effects, potentially improving efficacy and tolerability versus standard anti-seizure medicines. The company has no product revenue yet, but recently recognized collaboration revenue through a Greater China licensing deal with Tenacia. Long-term upside depends on successful commercialization of RAP-219 across epilepsy, bipolar disorder, chronic pain, and related CNS indications.